Pharma Pulse: GLP-1 Momentum Builds While Lilly Expands Genetic Medicine Manufacturing

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, supply chain dynamics, and healthcare innovation. I’m your host—let’s get into today’s headlines.

First up, Eli Lilly has opened its first dedicated genetic medicine facility in Lebanon, Indiana. The company says the site will support development and production of advanced therapies, marking a continued investment in expanding its capabilities in genetic medicine.

Next, GLP-1 therapies accounted for 8 out of every 100 prescriptions filled in March 2026, according to new data. The figure reflects the growing presence of these treatments across the US prescription market.

In dealmaking news, Bayer is acquiring Perfuse Therapeutics, adding to its work in ophthalmology. Meanwhile, Madrigal Pharmaceuticals has entered into a licensing agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, as both companies look to advance development efforts in MASH.

And finally, the FDA has authorized the first fruit-flavored electronic nicotine delivery system products, a decision that signals a major policy shift in how the agency is approaching flavored e-cigarette authorizations.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.